Terms: = Leukemia AND B2M, P61769, 567, ENSG00000166710 AND Treatment
55 results:
1. Health-related quality of life and its determinants among cancer patients: evidence from 12,148 patients of Indian database.
Dixit J; Gupta N; Kataki A; Roy P; Mehra N; Kumar L; Singh A; Malhotra P; Gupta D; Goyal A; Rajsekar K; Krishnamurthy MN; Gupta S; Prinja S
Health Qual Life Outcomes; 2024 Mar; 22(1):26. PubMed ID: 38481231
[TBL] [Abstract] [Full Text] [Related]
2. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
[TBL] [Abstract] [Full Text] [Related]
3. Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis.
Banerjee T; Kim MS; Haslam A; Prasad V
JAMA Intern Med; 2023 May; 183(5):435-441. PubMed ID: 36939665
[TBL] [Abstract] [Full Text] [Related]
4. The Addition of Hypomethylating Agents to Low-Intensity Induction Chemotherapy Does Not Improve Outcomes in Elderly Acute Myeloid leukemia Patients: A Single-Center Retrospective Study.
Liu D; Wang X; Tong J; Zhou L; Chen E; Zhou Z; Xue L; Zhang X; Sun G; Zheng C
Medicina (Kaunas); 2023 Jan; 59(1):. PubMed ID: 36676738
[No Abstract] [Full Text] [Related]
5. Association of Circulating Antibody-Secreting Cell Maturity With Disease Features in Primary Sjögren's Syndrome.
Steinmetz TD; Verstappen GM; Schulz SR; de Wolff L; Wilbrink R; Visser A; Terpstra J; Bootsma H; Kroese FGM
Arthritis Rheumatol; 2023 Jun; 75(6):973-983. PubMed ID: 36533856
[TBL] [Abstract] [Full Text] [Related]
6. Mortality Among Pediatric Patients With Acute Lymphoblastic leukemia in Sweden From 1988 to 2017.
Björk-Eriksson T; Boström M; Bryngelsson IL; Lähteenmäki PM; Jarfelt M; Kalm M; Olsson DS
JAMA Netw Open; 2022 Nov; 5(11):e2243857. PubMed ID: 36441552
[TBL] [Abstract] [Full Text] [Related]
7. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial.
Dillon R; Maycock S; Jackson A; Fox S; Freeman S; Craddock C; Thomas C; Homer E; Leahy J; Mamwell A; Potter N; Russell N; Wei A; Ommen HB; Hemmaway C; Knapper S; Billingham L
BMC Cancer; 2022 Nov; 22(1):1174. PubMed ID: 36376888
[TBL] [Abstract] [Full Text] [Related]
8. A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.
Wang X; Hong Y; Meng S; Gong W; Ren T; Zhang T; Liu X; Li L; Qiu L; Qian Z; Zhou S; Zhao M; Zhai Q; Meng B; Ren X; Zhang H; Wang X
Clin Immunol; 2022 Oct; 243():109105. PubMed ID: 36055572
[TBL] [Abstract] [Full Text] [Related]
9. Donor natural killer cells trigger production of β-2-microglobulin to enhance post-bone marrow transplant immunity.
Ruggeri L; Urbani E; Chiasserini D; Susta F; Orvietani PL; Burchielli E; Ciardelli S; Sola R; Bruscoli S; Cardinale A; Pierini A; Piersma SR; Pasquino S; Locatelli F; Ramarli D; Velardi E; Binaglia L; Jimenez CR; Holländer GA; Velardi A
Blood; 2022 Dec; 140(22):2323-2334. PubMed ID: 35984965
[TBL] [Abstract] [Full Text] [Related]
10. Rationale and design of Children's Oncology Group (COG) study ACCL20N1CD: financial distress during treatment of acute lymphoblastic leukemia in the United States.
Beauchemin M; Santacroce SJ; Bona K; Dang H; Alexander S; Allen K; De Los Santos C; Fisher B; Muñeton-Castaño Y; Ponce O; Vargas S; Sugalski A; Sung L; Parsons S
BMC Health Serv Res; 2022 Jun; 22(1):832. PubMed ID: 35764995
[TBL] [Abstract] [Full Text] [Related]
11. T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion.
Morton LT; Wachsmann TLA; Meeuwsen MH; Wouters AK; Remst DFG; van Loenen MM; Falkenburg JHF; Heemskerk MHM
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288464
[TBL] [Abstract] [Full Text] [Related]
12. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
[TBL] [Abstract] [Full Text] [Related]
13. Hospitalization and mortality outcomes in the first 5 years after a childhood cancer diagnosis: a population-based study.
Steineck A; Chow EJ; Doody DR; Mueller BA
Cancer Causes Control; 2021 Jul; 32(7):739-752. PubMed ID: 33835282
[TBL] [Abstract] [Full Text] [Related]
14. Impact of age and treatment institution type on outcomes of patients treated for chronic lymphocytic leukemia in British Columbia, Canada.
Huang SJ; Gerrie AS; Young S; Tucker T; Bruyère H; Hrynchak M; Galbraith P; Al Tourah AJ; Dueck G; Noble MC; Ramadan KM; Tsang P; Hardy E; Sehn LH; Toze CL
Leuk Res; 2021 Apr; 103():106538. PubMed ID: 33647819
[TBL] [Abstract] [Full Text] [Related]
15. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis.
Strosberg J; Leeuwenkamp O; Siddiqui MK
Cancer Treat Rev; 2021 Feb; 93():102141. PubMed ID: 33418096
[TBL] [Abstract] [Full Text] [Related]
16. Interaction network of proteins associated with unfavorable prognosis in acute myeloid leukemia.
Rendon-Rodriguez JJ; Restrepo-Rodriguez LF; Rothlisberger S
Acta Biochim Pol; 2020 Dec; 67(4):475-483. PubMed ID: 33284559
[TBL] [Abstract] [Full Text] [Related]
17. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.
Passamonti F; Cattaneo C; Arcaini L; Bruna R; Cavo M; Merli F; Angelucci E; Krampera M; Cairoli R; Della Porta MG; Fracchiolla N; Ladetto M; Gambacorti Passerini C; Salvini M; Marchetti M; Lemoli R; Molteni A; Busca A; Cuneo A; Romano A; Giuliani N; Galimberti S; Corso A; Morotti A; Falini B; Billio A; Gherlinzoni F; Visani G; Tisi MC; Tafuri A; Tosi P; Lanza F; Massaia M; Turrini M; Ferrara F; Gurrieri C; Vallisa D; Martelli M; Derenzini E; Guarini A; Conconi A; Cuccaro A; Cudillo L; Russo D; Ciambelli F; Scattolin AM; Luppi M; Selleri C; Ortu La Barbera E; Ferrandina C; Di Renzo N; Olivieri A; Bocchia M; Gentile M; Marchesi F; Musto P; Federici AB; Candoni A; Venditti A; Fava C; Pinto A; Galieni P; Rigacci L; Armiento D; Pane F; Oberti M; Zappasodi P; Visco C; Franchi M; Grossi PA; Bertù L; Corrao G; Pagano L; Corradini P;
Lancet Haematol; 2020 Oct; 7(10):e737-e745. PubMed ID: 32798473
[TBL] [Abstract] [Full Text] [Related]
18. Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients.
Yamazaki K; Inagaki N; Moldaver D; Viana R; Kimura S
Cancer Sci; 2020 Jul; 111(7):2526-2535. PubMed ID: 32324296
[TBL] [Abstract] [Full Text] [Related]
19. IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia.
Ishdorj G; Streu E; Lambert P; Dhaliwal HS; Mahmud SM; Gibson SB; Banerji V; Marshall AJ; Johnston JB
Blood Adv; 2019 Jul; 3(14):2188-2198. PubMed ID: 31324639
[TBL] [Abstract] [Full Text] [Related]
20. Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front.
Saigi M; Alburquerque-Bejar JJ; Sanchez-Cespedes M
Oncogene; 2019 Aug; 38(31):5921-5932. PubMed ID: 31253869
[TBL] [Abstract] [Full Text] [Related]
[Next]
